Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 20Recruiting 10Terminated 4Active not recruiting 4Unknown 2Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 51Head & Neck 8Dermatologic 5Breast 3Thoracic 2Tumor-Agnostic 1Lymphoid 1Gynecologic 1Genitourinary 1

Conditions

Ovarian Neoplasms 1

Interventions

Paclitaxel 20Carboplatin 20Bevacizumab 13Radiotherapy 12Cisplatin 11Cyclophosphamide 8olaparib 6niraparib 6Taxes 6pembrolizumab 5Magnetic Resonance Spectroscopy 5Gemcitabine 5Biopsy 5talazoparib 4dostarlimab 4aldesleukin 4Specimen Handling 4Fulvestrant 4Doxorubicin 4fludarabine 3atezolizumab 3Topotecan 3Radiation 3NVP-BKM120 3Methods 3Metformin 3Letrozole 3Hyperthermic Intraperitoneal Chemotherapy 3Early Intervention, Educational 3Colposcopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Fluorouracil × Gynecologic × Clear all
NCT03197584 2025-02-21

QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡